Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHENQI-HUA-YU formula (参芪化瘀方) is a Traditional Chinese Medicine (TCM) herbal formulation developed by the Hospital of Chengdu University of Traditional Chinese Medicine. It is primarily investigated for the prevention and treatment of diabetic macrovascular diseases, including diabetic lower extremity artery disease (LEAD), coronary atherosclerotic heart disease, and peripheral artery disease in patients with type 2 diabetes mellitus. The formula is based on the TCM theory of 'Latent Pathogen' and is often utilized as part of a 'Shen-Qi Sequential Therapy' strategy. Clinical trials have focused on its efficacy and safety in improving cardiovascular outcomes and vascular health in diabetic populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SHENQI-HUA-YU formula.